By. Allen WilbanksDate. 11/23/2023Lot Aronson, MD, a medical doctor and researcher from the Department of Gynecologic Oncology in the Netherlands…
Browsing: Ovarian
Harnessing the Power of Dostarlimab to Treat Advanced or Recurrent Endometrial Cancer Endometrial cancer remains a significant challenge for medical…
The recent approval by the Food and Drug Administration (FDA) of mirvetuximab soravtansine-gynx (Elahere) marks a significant advancement in the…
Rafael G. Amado, M.D., President, Head of Global Oncology Research and Development, leading and overseeing the company’s global oncology research…
Ovarian Cancer Treatment: What to Watch for In New and Novel Trials Shannon Westin MD By Shannon Westin, MD, MPH…
SOLO-1 Phase 3 [2022]: Newly Diagnosed Advanced Ovarian Cancer Research  Dr. Greg Rossi talks with OncologyTube about the SOLO-1…
Rebecca S. Kristeleit, MD, Ph.D., FRCP, specialises in the treatment of gynaecological cancers including cervical, endometrial and ovarian cancer. She…
Rebecca S. Kristeleit, MD, Ph.D., FRCP, specialises in the treatment of gynaecological cancers including cervical, endometrial and ovarian cancer. She…
Nichole James, Ph.D., Assistant Professor of Obstetrics and Gynecology (Research) at Brown University and Women and Infants Hospital. In this…
Nichole James, Ph.D., Assistant Professor of Obstetrics and Gynecology (Research) at Brown University and Women and Infants Hospital. In this…
Rebecca S. Kristeleit, MD, Ph.D., FRCP, specialises in the treatment of gynaecological cancers including cervical, endometrial and ovarian cancer. She…
Rebecca S. Kristeleit, MD, Ph.D., FRCP, specialises in the treatment of gynaecological cancers including cervical, endometrial, and ovarian cancer. She…
Bradley J. Monk, MD, FACOG, FACS, at GOG Foundation, HonorHealth Research Institute, University of Arizona College of Medicine, Creighton University…
Bradley J. Monk, MD, FACOG, FACS, at GOG Foundation, HonorHealth Research Institute, University of Arizona College of Medicine, Creighton University…
Oliver Dorigo, MD, Principal Investigator of the DeCidE1 study and Director of the Gynecologic Oncology Service at Stanford University speaks…
Oliver Dorigo, MD, Principal Investigator of the DeCidE1 study and Director of the Gynecologic Oncology Service at Stanford University speaks…
David M. O’Malley, MD, Department of Obstetrics and Gynecology at The Ohio State University College of Medicine and the director…
David M. O’Malley, MD, Department of Obstetrics and Gynecology at The Ohio State University College of Medicine and the director…
Prof. Lukas Rob, MD, Ph.D., Head of Obstetrics and Gynecological Oncology at University Hospital Kralovske Vinohrady speaks about the ASCO…
Prof. Jonathan Ledermann from the UCL Cancer Institute, University College London speaks about eUpdate – Newly Diagnosed Epithelial Ovarian Carcinoma…
Oliver Dorigo, MD, Ph.D., Principal Investigator of the DeCidE1 study and Director of the Gynecologic Oncology Service at Stanford University…
Oliver Dorigo, MD, Ph.D., Principal Investigator of the DeCidE1 study and Director of the Gynecologic Oncology Service at Stanford University…
Prof. Jonathan Ledermann from the UCL Cancer Institute, University College London speaks about eUpdate – Newly Diagnosed Epithelial Ovarian Carcinoma…
Prof. Lukas Rob, MD, Ph.D., Head of Obstetrics and Gynecological Oncology at University Hospital Kralovske Vinohrady speaks about the ASCO…
Richard T Penson, MD, MRCP, Associate Professor, Medicine, Harvard Medical School, and Clinical Director, Medical Gynecologic Oncology, Massachusetts General Hospital…
David Berd, MD Biovaxys And The World Ovarian Cancer Coalition Join Forces For May 8th, World Ovarian Cancer Day.Link to…
Jennifer Ribeiro, Ph.D. Assistant Professor of Obstetrics and Gynecology (Research) at Brown University and Women & Infants speaks about the…
Rachel Grisham, MD of Memorial Sloan Kettering Cancer Center speaks about Verastem Oncology Initiates Phase 2 Registration-Directed Trial of VS-6766…
W. Michael Korn, MD, CMO of Caris Life Sciences discusses their abstract – Caris Life Sciences Presented New Ovarian Cancer…
Robert Coleman, MD, FACOG, FACS, Chief Scientific Officer US Oncology Research discusses ASCO 2020 A phase III randomized controlled trial…
Stephen B. Edge MD, FACS, FASCO of Roswell Park Comprehensive Cancer Center speaks about the ASCO 2020 Going off pathway:…
Melissa Ann Geller, MD of the University of Minnesota speaks about the ASCO 2020 abstract APOLLO: A phase I study…
Anca Chelariu- Raicu, MD of MD Anderson Cancer Center speaks about the ASCO 2020 abstract Phase I/II study of weekly…
Jan Ole Kemnade, MD, Ph.D. from Baylor College of Medicine discusses and ASCO 2020 abstract entitled Computational discovery of non-mutational…
Rebecca Christian Arend, MD at University of Alabama discusses an abstract from ASCO 2020 Clinical trial in progress: Pivotal study…
Kathleen N. Moore, MD from OU Medicine discusses an ASCO 2020 abstract entitled MIRASOL (GOG 3045/ENGOT OV-55): A randomized, open-label,…
Denise Manon Langabeer, MBA, Ph.D. of MD Anderson gives an overview from ASCO 2020 the abstract entitled Are symptoms distinguishable…
Mansoor Raza Mirza, MD from Region Hovedstaden discusses an abstract from ASCO 2020 entitled Final survival analysis of NSGO-AVANOVA2/ENGOT-OV24: Combination…
Sepideh Azarianpour-Esfahani, Ph.D. of Case Western Reserve University discusses an abstract from ASCO 2020 Computerized features of spatial arrangement of…
Thanh Hue Dellinger, MD from the City of Hope discusses an ASCO 2020 abstract entitled Whole transcriptome changes correlate to…
Sonny Hsiao, Ph.D. of Acopedia shares his final thoughts on Acepodia Presents Preclinical Data on its Lead NK Cell Therapy…
Sonny Hsiao, Ph.D. of Acopedia discusses Acepodia Presents Preclinical Data on its Lead NK Cell Therapy Candidate ACE1702 at 2020…
Debra L. Richardson, MD – Sarah Cannon discusses Phase I expansion study of XMT-1536, a novel NaPi2b-targeting antibody-drug conjugate (ADC):…
Quincy S. Chu, MD – University of Alberta discusses A phase Ib study of oral Chk1 inhibitor LY2880070 in combination…
Quincy S. Chu, MD – University of Alberta discusses A phase Ib study of oral Chk1 inhibitor LY2880070 in combination…
Rodney Paul Rocconi, MD University of South Alabama discusses A phase I combination study of GMCSF/bi-shRNA(furin) DNA-transfected autologous tumor immunotherapy…
Rodney Paul Rocconi, MD University of South Alabama discusses A phase I combination study of GMCSF/bi-shRNA(furin) DNA-transfected autologous tumor immunotherapy…
Rodney Paul Rocconi, MD University of South Alabama discusses A phase I combination study of GMCSF/bi-shRNA(furin) DNA-transfected autologous tumor immunotherapy…
Marco Timmers, Ph.D., CEO – Byondis discusses Byondis develops new biological and chemical entities, a proprietary linker-drug platform to generate…
Marco Timmers, Ph.D., CEO – Byondis discusses Byondis develops new biological and chemical entities, a proprietary linker-drug platform to generate…
Marco Timmers, Ph.D., CEO – Byondis discusses Byondis develops new biological and chemical entities, a proprietary linker-drug platform to generate…
Marco Timmers, Ph.D., CEO – Byondis discusses Byondis develops new biological and chemical entities, a proprietary linker-drug platform to generate…
In this edition of The Onco’Zine Brief, Peter Hofland talking with Helen Sabzevari, the president of Precigen. Precigen is a…
Robert L. Coleman, MD of MD Anderson Cancer Center discusses the phase III randomized controlled trail of SSC followed by…
Robert L. Coleman, MD of MD Anderson Cancer Center discusses the phase III randomized controlled trail of SSC followed by…
Robert L. Coleman, MD of MD Anderson Cancer Center discusses the phase III randomized controlled trail of SSC followed by…
Elizabeth Swisher, MD of UW Medicine @UWMedicine discusses characterization of patients with long-term responses to rucaparib in recurrent ovarian cancer.…
Elizabeth Swisher, MD of UW Medicine @UWMedicine discusses characterization of patients with long-term responses to rucaparib in recurrent ovarian cancer.…
Richard Penson, MD of Massachusetts General Hospital @MassGeneralNews discusses a randomized phase III of olaparib versus nonplatinum chemotherapy in patients…
Richard Penson, MD of Massachusetts General Hospital @MassGeneralNews discusses a randomized phase III of olaparib versus nonplatinum chemotherapy in patients…
Earn CME: https://www.naccme.com/program/19-cpc-101-6 This webcast features a presentation by Dr. Alexander B. Olawaiye that discusses the integration of PARP inhibitors…
Heidi Gray, MD @heidigraydrezn5 of @SeattleCCA @UWashOBGYN discusses the phase I/II study of ruxolitinib with front-line neoadjuvant and post-surgical therapy…
Curtis McCloskey, PhD of @ottawahospital explains how this affects treatment and clinicians today. __________ A laboratory study published in Clinical…
Curtis McCloskey, PhD of @ottawahospital provides insight on a possible new frontier for preventing ovarian cancer. ____________ A laboratory study published…
A laboratory study published in Clinical Cancer Research provides a new perspective on how ovarian cancer is developed and suggests…
Nearly 14,000 women will die from ovarian cancer in 2019. Now, new research has found that women who use IUDs…
Earn CME credit: https://www.naccme.com/program/2018-i7956-1 PARP inhibitors are the most commonly used targeted therapy for patients with recurrent ovarian cancer, and…
Earn CME credit for this activity: https://www.naccme.com/program/2018-802-03 This on-demand activity examines the implications of BRCA mutational status, BRCAness, synthetic lethality,…
Speaking about symptoms can often be a difficult experience for patients, as it can confirm their fears of the disease.…
The diagnosis of ovarian cancer often occurs in the late stages due to a lack of adequate screening facilities. However,…
Physicians who are dealing with gynecological tumors have a limited experience of how to deal with the complications and toxicity…